ARGENX SE

Argenx’s Phase‑III study of Efgartigimod shows significant muscle‑strength gains for autoimmune myositis, boosting investor confidence and paving the way for regulatory filings.

Argenx’s Q2 2026 results surge 60% as Vyvgart dominates sales, driving revenue to $1.52B and EPS to $7.32, with future pipeline readouts poised to broaden growth.

Argenx SE’s “Overweight” upgrade by Barclays highlights its 5,685% decade‑long growth, strong biotech pipeline, and resilience amid European market volatility.

Argenx SE, a leading biotechnology company, has reported impressive half-year financial results, exceeding market expectations with a GAAP EPS of $6.32 and revenue of $1.74 billion.

Argenx SE is preparing to release its financial results, highlighting the company’s ongoing commitment to advancing healthcare through innovative antibody-based therapies in the biotechnology industry.

Argenx SE, a biotechnology company, is making significant strides in treating severe autoimmune diseases and cancer with its innovative antibody-based therapies, including a promising candidate set to enter a registrational trial for Congenital Myas…

Argenx SE has secured European Commission approval for its innovative VYVGART subcutaneous injection, marking a significant milestone in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Argenx SE’s treatment VYVGART has received a positive opinion from the European CHMP, paving the way for potential approval and marking a significant milestone in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).